Mip3a/relMtb
The Mip3a/relMtb vaccine is an intranasal therapeutic DNA fusion vaccine encoding the M. tuberculosis stringent response antigen relMtb (Rv2583c) linked to the immature dendritic cell–targeting chemokine Mip3a/CCL20, formulated as a plasmid DNA construct without an added adjuvant.
Read Moremc2-CMX
The mc2-CMX vaccine is a live attenuated vaccine that was developed using M. tuberculosis Ag85, MPT-51 and HSP-x to generate a fusion protein called CMX. The nucleotide sequences corresponding to epitopes 85 to 159 bp of Ag85C and 91 to 112 bp of MPT51 and HSP-x. The gene sequence was inserted in the genome of…
Read MoreALHA
Ag85A-LpqH (AL) is a recombinant subunit vaccine that combines the T cell-stimulating antigen Ag85A with the humoral immunity-targeting antigen LpqH. It is constructed using the pET-21a(+) vector, expressed in E. coli BL21(DE3), and formulated with aluminum for subcutaneous administration.
Read MoreNETB-EA
The Khader Lab in collaboration with EclipTB Inc andBlueWillow Biologics Inc., have developed an intranasal booster sub-unit, mucosal vaccine comprising of Mtb immunodominant antigens Early secreted antigenic target 6 kDa andAntigen 85B together with nanoemulsion adjuvant NE01-NETB-EA.
Read MoreTBvac-1, TBvac-2, TBvac-10
TBvac-1, TBvac-2, and TBvac-10 use a recombinant tri-segmented Pichinde virus (PICV) vector (rP18tri) to express M. tuberculosis antigens. TBvac-1 and TBvac-2 encode Ag85B, EsxA/ESAT-6, and EsxH/TB10.4, with antigen locations swapped between S1 and S2 segments. TBvac-10 encodes Ag85B, EsxH/TB10.4, RpfA, and Rv1733c. Vaccine stocks are produced in BHK-21 cells from plaque purified virus.
Read More